Intrinsic coagulation pathway factor

Intrinsic coagulation pathway factors are a group of blood proteins/zymogens, primarily serine proteases, that initiate blood clotting through the so-called "contact activation pathway." The key factors include Factor XII (Hageman factor), Factor XI (plasma thromboplastin antecedent), Factor IX (Christmas factor), and Factor VIII (antihemophilic factor), though the broader pathway ultimately converges on the common pathway using Factors X, V, II (prothrombin), and I (fibrinogen). Activation of these factors, typically initiated by contact with subendothelial collagen, leads to a cascade of proteolytic reactions culminating in the formation of a fibrin clot. These factors play essential roles in hemostasis and are relevant in multiple disease states, including bleeding disorders (e.g., hemophilias), thrombosis, and some inflammatory conditions. Deficiency of most intrinsic pathway factors causes bleeding disorders, except for Factor XII, whose deficiency prolongs aPTT but does not result in bleeding. The intrinsic pathway is a major target for anticoagulant therapy, including established and emerging drugs, as it contributes to both hemostasis and pathological clot formation. Note: The term "Intrinsic coagulation pathway factors" refers to a pathway involving several specific proteins, not a single molecular target; for drug discovery or diagnostic purposes, the preferred target is the individual factor (e.g., "Coagulation factor IX"), not the pathway as a group.

Other names

Intrinsic clotting factorIntrinsic pathway factorContact activation pathway factorsIntrinsic coagulation factors

Anticoagulants typically act by inhibiting the activation of specific intrinsic pathway factors (e.g., heparin potentiates antithrombin to inactivate factor IXa, Xa, XIa). Factor-replacement therapy restores deficient intrinsic factors in hemophilia or bleeding disorders. Factor XIa inhibitors selectively block the activation of factor XI to reduce thrombosis risk with less bleeding than traditional anticoagulants. Direct inhibition of downstream factors (e.g., thrombin or factor Xa) blocks the final steps of clot generation.